日韩A∨无码成人精品国产,激情A片久久久久久久,无码天堂va亚洲va在线va免费无码又爽又刺激高潮虎虎视频,伊人无码精品久久一区二区,婷婷激情五月一区二区三区播放中美女 赤裸 一区二区三区,精品亚洲成A人片在线观看少妇,亚洲欧美综合国产不卡,国产精品亚洲а∨天堂免

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
国产福利电影一区二区三区| 国产SUV精品一区二区6| 香港午夜三级A三级三点在线观看| 99久久人妻无码精品系列| 无码国产精成人午夜视频不卡| 久久午夜夜伦鲁鲁片免费无码影视| 人妻 偷拍 无码 中文字幕| 国模大尺度视频一区二区| 午夜欧美精品久久久久久久| 中文字幕人妻伦伦| 国产av无码专区亚洲av软件| 国产凹凸在线一区二区| 国产精品自在拍首页视频8| 国产精品偷伦视频| 亚洲精品国产成人片在线观看一区二区三区日韩| 一区二区三区无码按摩精油| 最新国产美女菊爆在线播放| 欧美级婬片A片免费播放口r| 美女粉嫩极品国产在线2020| H动漫无遮挡成本人H视频| 天天日天天插欧美日韩手机在线| 日韩一精品视频在线观看| 日日碰狠狠添天天爽超碰97久久| 国产美女裸体丝袜喷水视频| 久久精品国产亚洲AV果冻传媒| 国产午夜无码精品免费看性色| 日本与青年少妇毛茸茸高潮| 人妻换人妻AA视频麻豆| 欧美高清在线精品一区| 国产又爽又黄无遮挡的视频| 巨胸美乳中文在线观看| 无码高清人妻碎红楼| 自拍偷自拍亚洲精品10P| 国产成人毛片亚洲精品不卡| 日韩精品青青久久久| 精品国精品国产自在久国产应用| 国产麻豆9l精品三级站| 国产人妻少妇精品视频在线a | 国产精品一区二区久久精品| 欧美一区二区日韩一区二区| 日本不卡一区二区三区|